dr. joe kuti’s scholarship - hartford hospital library/unassigned/kutischolarship.pdf · dr. joe...

Dr. Joe Kuti’s Scholarship

11/7/11 1

1. Quintiliani R, Kuti JL. Drug therapy for methicillin-resistant Staphylococcus

aureus. Connecticut Medicine 2001;65(1):23-25.

2. Kuti JL, Quintiliani R. Cefditoren pivoxil: A novel broad-spectrum oral cephalosporin. Formulary 2001;36:265-275.

3. Mattoes HM, Kim MK, Kuti JL, Quintiliani R, Nicolau DP. Clinical advantages

of continuous infusion β-lactams. Ochsner Clinic Report on Serious Hospital Infections 2001;13(3):1-8.

4. Caron MF, Kuti JL, Quintiliani R, White CM. Drotrecogin alfa (activated): A

new approach to treating sepsis. Formulary 2001;36(11):784-795.

5. Kuti JL, Grant EM, Sutherland CA, Ye M, Zhou W, McCarter Y, Nightingale CH, Nicolau DP. Divergence in MIC distributions of Pseudomonas aeruginosa for piperacillin and piperacillin/tazobactam. J Infect Dis Pharmacother 2001;5(3):41-51.

6. Kuti JL. Cefditoren pivoxil: A viewpoint. (Guest Commentary). Drugs

2002;62(2):337-338.

7. Grant EM, Kuti JL, Nicolau DP, Nightingale CH, Quintiliani R. Clinical efficacy and pharmacoeconomics of a continuous infusion piperacillin/tazobactam program in a large, community, teaching hospital. Pharmacotherapy 2002;22(4):471-483.

8. Kuti JL, Capitano B, Nicolau DP. Cost-effective approaches to the treatment of

community acquired pneumonia in the era of resistance. Pharmacoeconomics 2002;20(8):513-528.

9. Florea NR, Kuti JL, Quintiliani R. Voriconazole (Vfend): A novel azole

antifungal. Formulary 2002;37(8):387-398.

10. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic profile of continuously infused piperacillin/tazobactam against Pseudomonas aeruginosa using Monte Carlo analysis. Diagn Microbiol Infect Dis 2002;44(1):51-57.

11. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomic

impact of a pharmacist managed automatic intravenous (IV) to oral (PO) conversion program. Amer J Health-Syst Pharm 2002;59(22):2209-2215.


11/7/11 2

12. Kuti JL, Caron MF. Drotrecogin alfa (activated) (Xigris). Antibiotics for

Clinicians 2002;6:113-119.

13. Kuti JL. Antibiotic treatment of catheter-related bacteremia in the hemodialysis patient. Connecticut Medicine 2003;67(2):85-88.

14. Kuti JL, Maglio D, Nightingale CH, Nicolau DP. Economic benefit of a

pharmacodynamic influenced meropenem dosing strategy. Am J Health-Syst Pharm 2003;60:565-568.

15. Florea NR, Kuti JL, Nightingale CH, Nicolau DP. Treatment of Clostridium

difficile-associated disease (CDAD). Connecticut Medicine 2003;67(3):153-155.

16. Kotapati SL, Kuti JL, Nightingale CH, Nicolau DP. Role of pharmacodynamics in designing dosage regimens for β-lactams. Connecticut Medicine 2003;67(5):265-268.

17. Kuti JL. Cost considerations in the use of antibiotics for the treatment of

community-acquired respiratory tract infections. In Nightingale CH, Ambrose PG, File TM Jr., eds. Community-Acquired Respiratory Infections: Antimicrobial Management. New York, NY: Marcel Dekker 2003;43-58.

18. Kuti JL, Dandekar PK, Nightingale CH, Nicolau DP. Use of Monte Carlo

simulation to design an optimized pharmacodynamic dosing strategy for meropenem. J Clin Pharm 2003;43:1116-1123.

19. Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. Cost

analysis of continuous versus intermittent infusion piperacillin/tazobactam: a time motion study. Am J Health-Syst Pharm 2003;60:2321-2327.

20. Sun HK, Kuti JL, Nicolau DP. Daptomycin: A novel lipopeptide antibiotic for

the treatment of resistant gram-positive infections. Formulary 2003;38:634-645.

21. Perkerson KA, Kuti JL, Nicolau DP. Clinical pharmacokinetics of carbapenems. Antibiotics for Clinicians 2003;7(suppl 2):24-29.

22. Kotapati S, Kuti JL, Nicolau DP. Role of a clinical pharmacist on drotrecogin

alfa outcomes in a large, community, teaching hospital. J Infect Dis Pharmacother 2003;6(3):55-68.


11/7/11 3

23. Ong CT, Kuti JL, Nightingale CH, Nicolau DP. Emerging Pseudomonas aeruginosa resistance: implications in clinical practice. Connecticut Medicine 2004;68:11-15.

24. Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of

meropenem and imipenem against Enterobacteriaceae, Acinetobacter baumannii, and Pseudomonas aeruginosa. Pharmacotherapy 2004;24(1):8-15.

25. Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP.

Pharmacoeconomic analysis of amphotericin B lipid complex versus liposomal amphotericin B in the treatment of fungal infections. Pharmacoeconomics 2004;22(5):301-310.

26. Kuti JL, Nightingale CH, Knauft F, Nicolau DP. Pharmacokinetic properties and

stability of continuous infusion meropenem in adults with cystic fibrosis. Clin Therapeutics 2004;26(4):493-501.

27. Kiffer CRV, Mendes C, Kuti JL, Nicolau DP. Pharmacodynamic Comparisons

of Antimicrobials against Nosocomial Isolates of E. coli, K. pneumoniae, A. baumannii and P. aeruginosa from the MYSTIC Surveillance Program: The OPTAMA Program, South America 2002. Diagn Microbiol Infect Dis 2004;49:109-116.

28. Kotapati S, Nicolau DP, Nightingale CH, Kuti JL. Clinical and economic

benefits of a meropenem dosing strategy based on pharmacodynamic concepts. Am J Health-Syst Pharm 2004;61:1264-1270.

29. Kuti JL, Nightingale CH, Nicolau DP. Optimizing pharmacodynamic target

attainment using the MYSTIC antibiogram: Data collected in North America in 2002. Antimicrob Agents Chemother 2004;48:2464-2470.

30. Mattoes HM, Kuti JL, Drusano GL, Nicolau DP. Optimizing antimicrobial

pharmacodynamics: dosage strategies for meropenem. Clin Therapeutics 2004;26:1187-1198.

31. Gillespie EL, Kuti JL, Nicolau DP. Appropriate antimicrobial therapy for

patients with severe infections. Antibiotics for Clinicians 2004;8:265-270.

32. Kuti JL, Moss KM, Nicolau DP, Knauft FR. Empiric treatment of multidrug-resistant Burkholderia cepacia lung exacerbation in a patient with cystic fibrosis:


11/7/11 4

Application of pharmacodynamic concepts to meropenem therapy. Pharmacotherapy 2004;24(11):1641-1645.

33. Florea NR, Kuti JL, Nightingale CH, Nicolau DP. IV to oral conversion

programs for anti-infectives in the United States: prevalence and characteristics. Hospital Pharmacy 2004;39:1069-1075.

34. Masterton RG, Kuti JL, Turner PJ, Nicolau DP. The OPTAMA programme:

utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. J Antimicrob Chemother 2005;55:71-77.

35. Sircar-Ramsewak F, Kuti JL, Nicolau DP. Posaconazole: A novel triazole

antifungal for the treatment of invasive fungal infections. Formulary 2005;40:13-21.

36. Kuti JL, Nicolau DP. Application of Pharmacodynamic Principles: From Theory

to Practice. In: Owens RC Jr., Nightingale CH, Ambrose PG, eds. Antibiotic Optimization: Concepts and Strategies in Clinical Practice. New York, NY: Marcel Dekker 2005;353-381.

37. Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. The clinical and

economic benefits of administering piperacillin/tazobactam by continuous infusion. Intensive and Critical Care Nursing 2005;21:87-93.

38. Gillespie EL, Kuti JL, Nicolau DP. When “S” doesn’t mean success: the

importance of choice of antibiotic and dose on clinical and economic outcomes of severe infections. Connecticut Medicine 2005;69(4):203-210.

39. Kuti JL. Effect of infusion duration on beta-lactam antibiotic pharmacodynamics:

who knew it mattered? Contagion 2005;2(4):154-157.

40. DeRyke CA, Kuti JL, Nicolau DP. Questioning the paradigm: monotherapy versus combination antimicrobial therapy for treatment of Pseudomonas aeruginosa. Connecticut Medicine 2005;69(5):271-275.

41. Kuti JL, Horowitz S, Nightingale CH, Nicolau DP. Comparison of

pharmacodynamic target attainment between healthy subjects and patients for ceftazidime and meropenem. Pharmacotherapy 2005;25(7):935-941.


11/7/11 5

42. Kuti JL, Nicolau DP. Derivation of meropenem dosage in patients receiving continuous veno-venous hemofiltration based on pharmacodynamic target attainment. Chemotherapy 2005;51(4):211-216.

43. Nicolau DP, Kuti JL. Optimizing antibiotic-related outcomes in the critically ill

patient. Infect Dis Clin Pract 2005;13:158-164.

44. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population pharmacokinetics and pharmacodynamics of piperacillin/tazobactam in patients with complicated intra-abdominal infection. J Antimicrob Chemother 2005;56:388-395.

45. Maglio D, Kuti JL, Nicolau DP. Simulation of antibiotic pharmacodynamic

exposure for the empiric treatment of nosocomial bloodstream infections: a report from the OPTAMA program. Clin Therapeutics 2005;27(7):1032-1042.

46. Lee SY, Kuti JL, Nicolau DP. Antimicrobial management of complicated skin

and skin structure infections in the era of emerging resistance. Surg Infect (Larchmt) 2005;6(3):283-295.

47. Kotapati S, Kuti JL, Nicolau DP. Pharmacodynamic modeling of β-lactam

antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA Program. Surg Infect (Larchmt) 2005;6(3):297-304.

48. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the

empiric treatment of nosocomial pneumonia: a report from the OPTAMA Program. Crit Care Med 2005;33:2222-2227.

49. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical implications of extended spectrum β-Lactamases (ESBL) producing Klebsiella species and Escherichia coli on cefepime effectiveness. J Infection 2005;51:211-217.

50. Gillespie EL, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials:

treatment optimisation. Expert Opin Drug Metab Tox 2005;1(3):351-361.

51. Kuti JL, Nicolau DP. Making the most of surveillance studies: summary of the OPTAMA Program. Diagn Microbiol Infect Dis 2005;53:281-287.

52. Ellis JM, Kuti JL, Nicolau DP. Use of Monte Carlo simulation to assess the

pharmacodynamics of β-lactams against Pseudomonas aeruginosa infections in


11/7/11 6

children: A report from the OPTAMA Program. Clin Therapeutics 2005;27(11):1820-1830.

53. Du X, Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetics

and pharmacodynamics of meropenem in pediatric patients. J Clin Pharm 2006;46:69-75.

54. Lee SY, Kuti JL, Nicolau DP. Polymixins: older antibiotics for a new threat.

Connecticut Medicine 2006;70(1):25-28.

55. Deryke CA, Lee SY, Kuti JL, Nicolau DP. Optimizing dosing strategies of antibacterials utilizing pharmacodynamic principles: Impact on the development of resistance. Drugs 2006;66(1):1-14.

56. Ong CT, Kuti JL, Nicolau DP. Pharmacodynamic modeling of imipenem-

cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy of skin and soft tissue infections: a report from the OPTAMA Program. Surg Infect (Larchmt) 2005;6(4):419-426.

57. Eagye KJ, Kuti JL, Nicolau DP. Pharmacodynamic comparison of the

carbapenems against E. coli and Klebsiella spp. containing extended spectrum β-lactamases. Am J Infect Dis 2005;1(3):149-155.

58. Deryke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP. Pharmacoeconomics of

continuous versus intermittent infusion piperacillin/tazobactam for the treatment of complicated intra-abdominal infection. Am J Health-Syst Pharm 2006;63:750-755.

59. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamic evaluation of meropenem and

cefotaxime for pediatric meningitis: a report from the OPTAMA Program. Paediatr Drugs. 2006;8(2):131-138.

60. Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of

probability of target attainment calculated by Monte Carlo simulation with meropenem clinical and microbiological response for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents 2006;28(1):62-68.

61. Lee SY, Fan HW, Kuti JL, Nicolau DP. Update on daptomycin: the first approved lipopeptide antibiotic. Expert Opin Pharmacother 2006;7(1):1381-1397.


11/7/11 7

62. Kiffer CRV, Kuti JL, Eagye KJ, Mendes C, Nicolau DP. Pharmacodynamic profiling of imipenem, meropenem, and ertapenem against extended spectrum β-lactamase producing Escherichia coli and Klebsiella spp. from Brazil. Int J Antimicrob Agents 2006;28(4):340-344.

63. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large

urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. Chest 2006;130(3):807-814.

64. Li C, Kuti JL, Nightingale CH, Nicolau DP. Population pharmacokinetic analysis

and dosing regimen optimization of meropenem in adult patients. J Clin Pharm 2006;46(10):1171-1178.

65. Lee SY, Kuti JL, Nicolau DP. Pharmacodynamic performance of 9

antimicrobials in the empiric treatment of skin and soft tissue infections: a report from the OPTAMA Program. Infect Dis Clin Pract 2006;14(5):289-295.

66. Deryke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Serum bactericidal

activity of high-dose daptomycin with and without co-administration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species. Antimicrob Agents Chemother 2006;50(11):3529-3534.

67. Lau W, Mercer D, Itani K, Nicolau D, Kuti JL, Mansfield D, Dana A.

Randomized, open-label, comparative study of piperacillin/tazobactam administered by continuous infusion versus intermittent infusion for treatment of hospitalized patients with complicated intra-abdominal infection. Antimicrob Agents Chemother 2006;50(11):3556-3561.

68. Ludwig E, Konkoly-Thege M, Kuti JL, Nicolau DP. Optimizing antibiotic

dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian Hospitals. Int J Antimicrob Agents 2006;28(5):433-438.

69. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended

spectrum β-lactamase producing Escherichia coli and Klebsiella species on clinical outcomes and hospital costs: a matched cohort study. Infect Control Hosp Epidemiol 2006;27(11):1226-1232.


11/7/11 8

70. Deryke CA, Kuti JL, Nicolau DP. Changes in pharmacodynamic target attainment for antimicrobials over a 2-year period: results of the 2004 OPTAMA program in North America. Infect Dis Clin Pract 2007;15:26-34.

71. Kim SW, Kuti JL, Nicolau DP. Intracellular antibiotic penetration. Antibiotics

for Clinicians 2006;10:369-373.

72. Kioumis IP, Kuti JL, Nicolau DP. Intra-abdominal infections: considerations for the use of the carbapenems. Expert Opin Pharmacother 2007:8(2):167-182.

73. Laohavaleeson S, Kuti JL, Nicolau DP. Telavancin: a novel lipoglycopeptide for

resistant gram-positive infections. Expert Opin Investig Drugs 2007;16(3):347-357.

74. Deryke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment of six β-

lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. Pharmacother 2007;27(3):333-342.

75. Nicasio AM, Kuti JL, Nicolau DP, Quintiliani R. Practical therapeutics: oral

antibiotic treatment for infective endocarditis. Antibiotics for Clinicians 2007;1:396-401.

76. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with

extended spectrum β-lactamase (ESBL) and non-ESBL infections. J Infect 2007;54:463-468.

77. Eagye KJ, Kuti JL, Nicolau DP. Evaluating empiric treatment options for

secondary peritonitis using pharmacodynamic profiling. Surg Infect (Larchmt) 2007;8(2):215-226.

78. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in

patients with lower respiratory tract infections. Antimicrob Agents Chemother 2007;51(5):1725-1730.

79. Santos Filho L, Eagye KJ, Kuti JL, Nicolau DP. Addressing resistance evolution

in Pseudomonas aeruginosa using pharmacodynamic modeling: application to meropenem dosage and combination therapy. Clin Microbiol Infect 2007;13:579-585.


11/7/11 9

80. Kim A, Kuti JL, Nicolau DP. Review of dalbavancin, a novel semisynthetic lipoglycopeptide. Expert Opin Investig Drugs 2007;16(5):717-733.

81. Deryke CA, Kuti JL, Nicolau DP. The use of antibiotic pharmacodynamic

endpoints in incremental cost-effectiveness analyses: a novel approach for consideration during hospital formulary reviews. Formulary 2007;42:252-260.

82. Kiffer CRV, Kuti JL, Mendes CMF, Oplustil CP, Amarante JB, Biancalana ML,

Xavier N, Nicolau DP. A pharmacodynamic strategy to optimize empirical antibiotic therapy for gram-negative bacteria in a Brazilian intensive care unit. Brazilian J Infect Dis 2007;11(2):183-185.

83. Santos Filho L, Kuti JL, Nicolau DP. Employing pharmacokinetic and

pharmacodynamic principles to optimize antimicrobial treatment in the face of emerging resistance. Brazilian J Microbiol 2007;38:183-193.

84. Nicasio AM, Quintiliani R Jr., DeRyke CA, Kuti JL, Nicolau DP. Treatment of

Serratia marcescens meningitis with prolonged infusion of meropenem. Annals of Pharmacother 2007;41(6):1077-1081.

85. Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Empiric therapy for secondary

peritonitis: a pharmacodynamic analysis of cefepime, ceftazidime, ceftriaxone, imipenem, levofloxacin, piperacillin/tazobactam, and tigecycline using Monte Carlo simulation. Clin Ther 2007;29(5):889-899.

86. Coleman C, Kuti EL, Kuti JL. The Principals of Pharmacoeconomics. In

Nightingale CH, Ambrose PG, Drusano GL, Muradawa T, eds. Antimicrobial Pharmacodynamics in Theory and Clinical Practice, 2nd edition. New York, NY: Informa Healthcare, 2007; 487-503.

87. Deryke CA, Kuti JL, Nicolau DP. Re-evaluation of current susceptibility

breakpoints for Gram-negative rods based on pharmacodynamic assessment. Diagn Microbiol Infect Dis 2007;58:337-344.

88. Sahni JK, Kuti JL, Nicolau DP. Time required by pharmacy technicians to

reconstitute new versus old piperacillin/tazobactam formulations. J Pharm Tech 2007;23:203-206.

89. Berenholtz SM, Pronovost P, Ngo K, Barie P, Hitt J, Kuti JL, Lawlar N,

Schilling L, Dorman T, for the Core Sepsis Team. Developing quality measures for sepsis care in the ICU. Joint Comm J Qual Patient Saf 2007;33(9):559-568.


11/7/11 10

90. Wang H, Zhang B, Ni Y, Kuti JL, Chen B, Chen M, Nicolau DP.

Pharmacodynamic target attainment of seven antimicrobials against gram-negative bacteria collected from china in 2003 and 2004. Int J Antimicrob Agents 2007;30(5):452-457.

91. Kim A, Sutherland CA, Kuti JL, Nicolau DP. Optimal dosing of

piperacillin/tazobactam for the treatment of Pseudomonas aeruginosa infections: prolonged or continuous infusion? Pharmacother 2007;27(11):1490-1497.

92. Kuti JL. Pharmacoeconomic considerations when selecting antifungal therapy.

Eur J Hosp Pharm Prac 2007;13(6):64-66.

93. Kuti JL, Kiffer CRV, Mendes CMF, Nicolau DP. Pharmacodynamic comparison of linezolid, teicoplanin, and vancomycin against clinical isolates of Staphylococcus aureus and coagulase-negative staphylococci collected from hospitals in Brazil. Clin Microbiol Infect 2008;14:116-123.

94. Nicasio AM, Kuti JL, Nicolau DP. The current state of multidrug-resistant gram-

negative bacilli in the North America: insights from the Society of Infectious Diseases Pharmacists. Pharmacother 2008;28(2):235-249.

95. Kontou P, Kuti JL, Nicolau DP. Ceftobiprole: the first anti-MRSA cephalosporin

antibiotic. Formulary 2008;43:66-79.

96. Kim SW, Kuti JL, Nicolau DP. Inhaled antimicrobial therapies for respiratory infections. Curr Infect Dis Reports 2008;10:29-36.

97. Kuti JL, Dowzicky M, Nicolau DP. A pharmacodynamic simulation to assess

tigecycline efficacy for hospital-acquired pneumonia compared with other common intravenous antibiotics. J Chemother 2008;20(1):69-76.

98. Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance of

tigecycline versus common intravenous antibiotics for the empiric treatment of complicated skin and soft tissue infections. Surg Infect (Larchmt) 2008:9(1):57-66.

99. Nicasio AM, Kuti JL, Aslanzadeh J, Nicolau DP. Influence of automated

screening and confirmation of extended spectrum β-Lactamase producing Enterobacteriaceae on prescribing of antibiotics. J Med Microbiol 2008;57:1147-1151.


11/7/11 11

100. Fallon RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP. Pharmacodynamic

target attainment of oral β-lactams for the empiric treatment of acute otitis media in children. Pediatr Drugs 2008;10(5):329-335.

101. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. In vivo

microdialysis study of the penetration of daptomycin into soft tissues in diabetic versus healthy volunteers. Antimicrob Agents Chemother 2008;52(11):3941-3946.

102. Pichichero ME, Doern GV, Kuti JL, Nicolau DP. Probability of achieving

requisite pharmacodynamic exposure for oral β-lactam regimens against Hemophilus influenzae in children. Pediatr Drugs 2008;10(6):391-397.

103. Laohavaleeson S, Lolans K, Quinn JP, Kuti JL, Nicolau DP. Expression of the

MexXY-OprM efflux system in Pseudomonas aeruginosa with discordant cefepime / ceftazidime susceptibility profiles. Infect Drug Resist 2008;1:51-55.

104. Kiffer CRV, Kuti JL, Nicolau DP. Optimization of therapy using

pharmacodynamic principles: the case for extending the infusion duration for beta-lactam antibiotics. Brazilian J Infect Dis 2008;12(Suppl. 2):22-28.

105. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of

telavancin versus vancomycin for the treatment of complicated skin and skin structure infections. Pharmacotherapy 2008;28(12):1471-1482.

106. Kioumis IP, Kuti JL, Nicolau DP. Antibiotic therapy: general considerations

for use in the orthopedic patient. In: Browner J, ed. Skeletal Trauma: Basic Science, Management, and Reconstruction. 4th Edition. Saunders Elsevier, Philadelphia, PA. 2009; 258-264.

107. Kuti JL, Shore E, Palter M, Nicolau DP. Tackling empirical antibiotic therapy

for ventilator-associated pneumonia in your ICU: guidance for implementing the guidelines. Sem Resp Crit Care Med 2009;30:102-115.

108. Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital length of

stay and costs in patients with ventilator-associated pneumonia. Sem Resp Crit Care Med 2009;30:116-124.


11/7/11 12

109. Nicasio AM, Tessier PR, Nicolau DP, Shore E, Russomanno J, Knauft RF, Kuti JL. Bronchopulmonary disposition of micafungin in healthy adult volunteers. Antimicrob Agents Chemother 2009;53(3):1218-1220.

110. Crandon JL, Kuti JL, Jones RN, Nicolau DP. Comparison of 2002-2006

OPTAMA Programs for US Hospitals: Focus on Gram-Negative Resistance. Ann Pharmacother 2009;43:220-227.

111. Koomanachai P, Crandon JL, Kuti JL, Nicolau DP. Comparative

pharmacodynamics for intravenous antibiotics against gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Int J Antimicrob Agents 2009;33:348-353.

112. Kim A, Sakoulas G, Kuti JL, Nicolau DP. Prevalence of methicillin-resistant

Staphylococcus aureus strains with vancomycin MIC 2 mcg/mL in New York City area hospitals and implications on pharmacodynamic target attainment. Infect Dis Clin Pract 2009;17:95-98.

113. Nicasio AM, Ariano RE, Zelenitsky SA, Kim A, Crandon JL, Kuti JL, Nicolau

DP. Population pharmacokinetics of high-dose, prolonged-infusion cefepime in adult critically-ill patients with ventilator-associated pneumonia. Antimicrob Agents Chemother 2009;53(4):1476-1481.

114. Kuti EK, Kuti JL. Bacteriostatic versus bactericidal antimicrobials. Topics

Ocular Anti-Infect 2009;3:5-6.

115. Courter JD, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure for β-lactams using prolonged and continuous infusions in the pediatric population. Pediatr Blood Cancer 2009;53:379-385.

116. Kuti JL, Nicasio AM, Sutherland CA, Nicolau DP. Elevated vancomycin

minimum inhibitory concentrations among methicillin-resistant Staphylococcus aureus causing ventilator associated pneumonia at a Connecticut hospital. Connecticut Medicine 2009;73(6):337-340.

117. Nicasio AM, Kuti JL, Nicolau DP. Pharmacotherapy of complicated urinary

tract and intra-abdominal infections with doripenem. Clin Med Ther 2009:1;787-799.


11/7/11 13

118. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2009;30:746-752.

119. Bulik CC, Kuti JL, Nicolau DP. Clostridium difficile infection – not just a

burden anymore. Connecticut Medicine 2009;73(7):407-411.

120. Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Surgical site infections: does inadequate antibiotic therapy affect patient outcomes? Surg Infect 2009;10(4):323-331.

121. Kontou P, Kuti JL, Nicolau DP. Validation of the Infectious Diseases Society

of America / American Thoracic Society criteria to predict severe community-acquired pneumonia caused by Streptococcus pneumoniae. Am J Emergency Med 2009;27:968-974.

122. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS,

Russomanno JH, Shore E, Nicolau DP, Kuti JL. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults. Antimicrob Agents Chemother 2009;53(12):5102-5107.

123. Eagye KJ, Kuti JL, Sutherland CA, Christensen H, Nicolau DP. In vitro

activity and pharmacodynamics of commonly used antibiotics against adult systemic isolates of Escherichia coli and Pseudomonas aeruginosa at forty US hospitals. Clin Ther 2009;31(11):2678-2688.

124. Kim A, Kuti JL, Nicolau DP. Probability of pharmacodynamic target

attainment with standard and prolonged-infusion antibiotic regimens for empiric therapy in adults with hospital-acquired pneumonia. Clin Ther 2009;31(11):2765-2778.

125. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL.

Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother 2010;54(2):804-810.

126. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL.

Pharmacodynamic-based clinical pathway for empiric antibiotic choice in patients with ventilator-associated pneumonia. J Crit Care 2010;25:69-77.


11/7/11 14

127. Kuti JL, Nicolau DP. Optimal cefepime and meropenem dosing for ventilator-associated pneumonia patients with reduced renal function: an update to our clinical pathway. J Crit Care 2010;25:152-153.

128. Crandon JL, Bulik CC, Kuti JL, Nicolau DP. Clinical pharmacodynamics of

cefepime in patients infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 2010;54(3):1111-1116.

129. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic modeling

of intravenous antibiotics against gram-negative bacteria collected in the United States. Clin Ther 2010;32(4):766-779.

130. Nicasio AM, Eagye KJ, Kuti EL, Nicolau DP, Kuti JL. Length of stay and

hospital costs associated with a pharmacodynamic-based clinical pathway for empiric antibiotic choice for ventilator-associated pneumonia. Pharmacotherapy 2010;30(5):453-462.

131. Bulik CC, Fauntleroy KA, Jenkins SG, Abuali M, LaBombardi VJ, Nicolau DP,

Kuti JL. Comparison of meropenem MICs and susceptibilities for carbapenemase-producing Klebsiella pneumoniae isolates by various testing methods. J Clin Microbiol 2010;48(7):2402-2406.

132. Kuti EL, Kuti JL. Pharmacokinetics, antifungal activity and clinical efficacy of

anidulafungin in the treatment of fungal infections. Ex Opin Drug Metab Toxicol 2010;6(10):1287-1300.

133. Keel RA, Sutherland CA, Aslanzadeh J, Nicolau DP, Kuti JL. Correlation

between vancomycin and daptomycin MIC values for methicillin-susceptible and methicillin-resistant Staphylococcus aureus by 3 testing methodologies. Diagn Microbiol Infect Dis 2010;68:326-329.

134. Crandon JL, Kuti JL, Nicolau DP. Comparative efficacies of human simulated

exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model. Antimicrob Agents Chemother 2010;54(12):5115-5119.

135. Bulik CC, Wiskirchen DE, Shepard A, Sutherland CA, Kuti JL, Nicolau DP.

Tissue penetration and pharmacokinetics of tigecycline in diabetic patients with chronic wound infections described by using in vivo microdialysis. Antimicrob Agents Chemother 2010;54(12):5209-5213.


11/7/11 15

136. Bulik CC, Quintiliani R Jr, Pope JS, Kuti JL, Nicolau DP. Pharmacodynamics and tolerability of high-dose, prolonged infusion carbapenems in adults with cystic fibrosis – a review of 3 cases. Respir Med CME 2010;3:146-149.

137. Kim A, Kuti JL, Nicolau DP. Dalbavancin. In: Grayson ML, Crowe SM,

McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. Kucers’ The Use of Antibiotics, Volume 1, 6th Edition. London, UK: Hodder Arnold, 2010; 645-653.

138. Nicasio AM, Kuti JL, Nicolau DP. Telavancin. In: Grayson ML, Crowe SM,

McCarthy JS, Mills J, Mouton JW, Norrby SR, Paterson DL, Pfaller MA, eds. Kucers’ The Use of Antibiotics, Volume 1, 6th Edition. London, UK: Hodder Arnold, 2010; 654-660.

139. Koomanachai P, Keel RA, Johnson-Arbor KK, Suecof LA, Nicolau DP, Kuti

JL. Linezolid penetration into wound tissue of two diabetic patients before and after hyperbaric oxygen therapy. Undersea Hyperbaric Med 2011;38(1):11-16.

140. Roberts JA, Kwa A, Montakantikul P, Gomersall C, Kuti JL, Nicolau DP.

Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program – Asia-Pacific region. Int J Antimicrob Agents 2011;37:225-229.

141. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP.

Optimization of meropenem dosage in the critically ill population based on renal function. Intensive Care Med 2011:37:632-638.

142. Wiskirchen DE, Koomanachai P, Nicasio AM, Nicolau DP, Kuti JL. In vitro

pharmacodynamics of simulated pulmonary exposures of tigecycline alone and in combination against Klebsiella pneumoniae isolates producing a KPC carbapenemase. Antimicrob Agents Chemother 2011;55(4):1420-7.

143. Housman ST, Kuti JL, Nicolau DP. Ceftaroline: a novel cephalosporin with

methicillin-resistant Staphylococcus aureus and multidrug-resistant Streptococcus pneumoniae activity. Formulary 2011;46:71-81.

144. Sutherland CA, Nicolau DP, Kuti JL. Development of an HPLC method for the

determination of anidulafungin in human plasma and saline. J Chromatogr Sci 2011;49:397-400.


11/7/11 16

145. Keel RA, Schaeftlein A, Kloft C, Pope JS, Knauft RF, Muhlebach M, Nicolau DP, Kuti JL. Pharmacokinetics of intravenous and oral linezolid in adults with cystic fibrosis. Antimicrob Agents Chemother 2011;55(7):3393-3398.

146. Wiskirchen DE, Kuti JL, Nicolau DP. The use of scoring systems to predict

prognosis in patients with ventilator-associated pneumonia. Clin Pulm Med 2011;18:181-185.

147. Wiskirchen DE, Shepard A, Kuti JL, Nicolau DP. Determination of tissue

penetration and pharmacokinetics of linezolid in patients with diabetic foot infections using in vivo microdialysis. Antimicrob Agents Chemother 2011;55(9):4170-4175.


11/7/11 17

ABSTRACTS

1a. Kuti JL, Grant EM, Nicolau DP, Nightingale CH, Quintiliani R. Clinical Efficacy and Pharmacoeconomics of Piperacillin/Tazobactam Administered by Continuous versus Intermittent Infusion. [Abstract # RP-323] 35th Annual ASHP – Midyear Clinical Meeting, Las Vegas, NV, December 2000.

2a. Le TN, Kuti JL, Goldman M, Quercia R, Quintiliani R. Tracking Physician

Prescribing Trends for Intravenous to Oral Levofloxacin – A Cost Analysis to Validate a Pharmacist Run Automatic Conversion Program. 35th Annual ASHP – Midyear Clinical Meeting, Las Vegas, NV, December 2000.

3a. Kuti JL, Grant EM, Nicolau DP, Nightingale CH, Quintiliani R. Clinical Efficacy

and Pharmacoeconomics of Piperacillin/Tazobactam Administered by Continuous versus Intermittent Infusion. [Abstract #139E] The American College of Clinical Pharmacy – 2001 Annual Meeting, Tampa, FL, October 2001.

4a. Kuti JL, Nightingale CH, Quintiliani R, Nicolau DP. Pharmacodynamic Profile

of Continuously Infused Piperacillin/Tazobactam Against Pseudomonas aeruginosa using Monte Carlo Analysis. [Abstract #229E] The American College of Clinical Pharmacy – 2001 Annual Meeting, Tampa, FL, October 2001.

5a. Kuti JL, Le TN, Nightingale CH, Nicolau DP, Quintiliani R. Pharmacoeconomic

Impact of a Pharmacist Managed Automatic Intravenous (IV) to Oral (PO) Conversion Program. [Abstract # O-391] 41st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, December 2001.

6a. Kuti JL, Dandekar P, Nightngale CH, Nicolau DP. Pharmacodynamic

Comparison of Prolonged and Traditional Infusions of Meropenem in Gram-Negative Bacteria. [Abstract #A-637] 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2002.

7a. Kuti JL, Kotapati S, Williams P, Capitano B, Nightingale CH, Nicolau DP.

Pharmacoeconomic Analysis of Amphotericin B Lipid Complex Versus Liposomal Amphotericin B in the Treatment of Fungal Infections. [Abstract #O-1000] 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, September 2002.

8a. Kuti JL, Florea NR, Nightingale CH, Nicolau DP. Pharmacodynamics of

Meropenem and Imipenem Against Enterobacteriaceae and Pseudomonas


11/7/11 18

aeruginosa. [Abstract #62] 40th Annual Meeting of the Infectious Diseases Society of America, Chicago, IL, October 2002.

9a. Kotapati S, Kuti JL, Nicolau DP. Impact of an antibiotic management pharmacist

on drotrecogin alfa outcomes in a large, community, teaching hospital. Infection 2003, Las Vegas, NV, April 2003.

10a. Florea NR, Kuti JL, Nightingale CH, Nicolau DP. Prevalence and

characteristics of intravenous to oral conversion programs for anti-infectives in the United States. [Abstract #197] American College of Clinical Pharmacy, 2003 Spring Practice and Research Forum, Palm Springs, CA, April 2003.

11a. Kuti JL, Nightingale CH, Knauft F, Nicolau DP. Pharmacokinetics of

continuously infused meropenem in adults with cystic fibrosis. [Abstract #2135] 99th International Conference of the American Thoracic Society, Seattle, WA, May 2003.

12a. Florea NR, Kotapati S, Kuti JL, Geissler EC, Nightingale CH, Nicolau DP. Cost

analysis of continuous versus intermittent infusion piperacillin/tazobactam: a time motion study. [Abstract # P-57E] 2003 American Society of Health-System Pharmacists Summer Meeting, San Diego, CA, June 2003.

13a. Kuti JL, Kotapati, S, Nightingale CH, Nicolau DP. Evaluation of

Pharmacoodynamic Target Attainment between Healthy Subject and patient Data using Monte Carlo Simulation (Abstract #A-9). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003.

14a. Kuti JL, Nightingale CH, Nicolau DP. Optimizing Pharmacodynamic Target

Attainment using the MYSTIC Antibiogram (OPTAMA) – North America (NA) 2002 (Abstract #A-7). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003.

15a. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical and Economic

Outcomes of a Meropenem Dosing Protocol Based on Pharmacodynamic Concepts (Abstract #A-1364). 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Illinois, September 2003.

16a. Kiffer CRV, Mendes C, Kuti JL, Nicolau DP. Optimizing pharmacodynamic

target attainment using the MYSTIC antibiogram (OPTAMA) – South America, 2002 (Abstract #IH 101). Congresso Brasileiro de Microbiologia, Florianópolis - Santa Catarina – Brasil, November 17-20, 2003.


11/7/11 19

17a. Goldman MC, Hobbs LC, Kuti JL. Comprehensive vancomycin dosing and

monitoring program in a clinical setting (Abstract #434). 38th Midyear Meeting of the American Society of Health System Pharmacists, New Orleans, Louisiana, December 2003.

18a. Masterton R, Kuti JL, Nightingale C, Nicolau D. Optimizing pharmacodynamic

target attainment using the MYSTIC antibiogram (OPTAMA) – Acinetobacter sp. and P. aeruginosa in Europe, 2002 (Abstract #P1104). 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004.

19a. Masterton R, Kuti JL, Nightingale C, Nicolau D. Optimizing pharmacodynamic target attainment using the MYSTIC antibiogram (OPTAMA) – Escherichia coli and Klebsiella pneumoniae in Europe, 2002 (Abstract #P1105). 14th European Congress of Clinical Microbiology and Infectious Diseases, Prague, Czech Republic, May 1-4, 2004.

20a. Li C, Kuti JL, Nightingale CH, Mansfield DL, Dana A, Nicolau DP. Population

pharmacokinetics of continuous and intermittent infusion piperacillin/tazobactam in patients with complicated intra-abdominal infection (Abstract #375). World Conference on Dosing Anti-Infectives, Nürnberg, Germany, September 9-11, 2004.

21a. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical and microbiological

responses of different antibiotic classes on extended spectrum β-lactamase producing Klebsiella sp. and Escherichia coli infections (Abstract #443). 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, September 30 – October 3, 2004.

22a. Kuti JL, Nicolau DP. Pharmacodynamics of meropenem in patients receiving

continuous venovenous hemofiltration (CVVH) – a report from the 2003 OPTAMA Program (Abstract #316). 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, September 30 – October 3, 2004.

23a. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials against

Streptococcus pneumoniae in pediatric patients – a report from the OPTAMA Program (Abstract #314). 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, September 30 – October 3, 2004.


11/7/11 20

24a. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials against gram-negative bacteria in pediatric patients – a report from the OPTAMA Program (Abstract #315). 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, September 30 – October 3, 2004.

25a. Sun HK, Kuti JL, Nightingale CH, Nicolau DP. Pharmacodynamics of

RO4908463 (CS-023) for the empiric treatment of nosocomial pneumonia (Abstract #320). 42nd Annual Meeting of the Infectious Diseases Society of America, Boston, MA, September 30 – October 3, 2004.

26a. Kotapati S, Kuti JL, Nicolau DP. Pharmacodynamic comparison of β-lactam

antibiotics for the empiric treatment of secondary peritonitis: a report from the OPTAMA Program (Abstract 167). American College of Surgeons 90th Annual Clinical Congress, New Orleans, LA, October 10 –14, 2004.

27a. Ong CT, Kuti JL, Nicolau DP. Pharmacodynamic analysis of imipenem-

cilastatin, meropenem, and piperacillin-tazobactam for empiric therapy in surgical wound infections: a report from the OPTAMA Program (Abstract 215). American College of Surgeons 90th Annual Clinical Congress, New Orleans, LA, October 10 –14, 2004.

28a. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials against gram-negative bacteria in pediatric patients – a report from the OPTAMA Program (Abstract #266E). 2004 Annual Meeting American College of Clinical Pharmacy, Dallas, TX, October 25-28, 2004.

29a. Kuti JL, Nightingale CH, Nicolau DP. Pharmacodynamics of RO4908463 (CS-

023), a novel carbapenem, against Staphylococcus aureus and Pseudomonas aeruginosa (Abstract #A-141). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., October 30, 2004.

30a. Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Clinical and microbiological

response of extended spectrum β-lactamase producing Klebsiella sp. and Escherichia coli infections treated with cefepime (Abstract #K-1590). 44th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., November 1, 2004.

31a. Sykes RB, Sahani J, Ellis JM, Kuti JL. Retrospective comparison of lipid

amphotericin B complex (ABLC) and liposomal amphotericin B (L-AMB) in the pediatric population (Abstract 113). 2005 Spring Practice and Research Forum of


11/7/11 21

the American College of Clinical Pharmacy, Myrtle Beach, SC, April 10-13, 2005.

32a. Kuti JL, Ong C, Lo M, Melnick D, Soto N, Nicolau DP. Comparison of

pharmacodynamic target attainment calculated by Monte Carlo simulation with microbiological response for two carbapenems in the treatment of complicated skin and skin structure infections. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005.

33a. Sun HK, Kuti JL, Nicolau DP. Pharmacodynamics of antimicrobials for the

empiric treatment of nosocomial pneumonia: a report from the OPTAMA program. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005.

34a. Ludwig E, Maglio D, Konkoly-Thege M, Kuti J, Nicolau D. Pharmacodynamic

comparison of intravenous antimicrobials against Pseudomonas aeruginosa in Hungarian hospitals - A report from the OPTAMA Program. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005.

35a. Jones ME, Nicolau DP, Kuti JL, Nightingale C, Draghi DC, Flamm RK, Sahm

DF. Activity and pharmacodynamics of RO490-8463 (CS-023), a carbapenem with activity against MRSA. 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, Denmark, April 2-5, 2005.

36a. Ellis JM, Kuti JL, Nicolau DP. Pharmacodynamics of meropenem and

cefotaxime for pediatric meningitis – a report from the OPTAMA Program (Abstract #1359). 2005 Pediatric Academic Societies’ Annual Meeting, Washington D.C., May 14-17, 2005.

37a. Sun HK, Nicolau DP, Kuti JL. Resource utilization of adults admitted to a large

urban hospital with community-acquired pneumonia caused by Streptococcus pneumoniae. 2005 Annual Meeting of the American College of Clinical Pharmacy, San Francisco, CA, October 24, 2005.

38a. Deryke CA, Kuti JL, Mansfield D, Dana A, Nicolau DP. Pharmacoeconomics of

continuous versus intermittent infusion piperacillin/tazobactam for the treatment of hospitalized patients with complicated intra-abdominal infection (Abstract). 40th Midyear Meeting of the American Society of Health System Pharmacists, Las Vegas, Nevada, December 2005.


11/7/11 22

39a. Lee SY, Kuti JL, Nicolau DP. Impact of extended spectrum β-lactamase producing bacteria on hospital cost (Abstract #O-174). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., December 16, 2005.

40a. Lee SY, Kotapati S, Kuti JL, Nightingale CH, Nicolau DP. Impact of extended

spectrum β-lactamase producing bacteria on initial antibiotic outcomes: a case-controlled study (Abstract #K-1290). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., December 17, 2005.

41a. Lee SY, Kuti JL, Nicolau DP. Cefepime pharmacodynamics in patients with

extended spectrum β-lactamases (ESBL) and non-ESBL infections (Abstract #A-1151). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., December 17, 2005.

42a. Li C, Du X, Kuti JL, Nicolau DP. Clinical pharmacodynamics of meropenem in

adult patients with lower respiratory tract infections (Abstract #A-1147). 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., December 17, 2005.

43a. Lau W, Mercer D, Itani K, Nicolau D, Kuti JL, Mansfield D, Dana A. A

randomized, open-label, comparative study of piperacillin/tazobactam administered by continuous infusion versus intermittent infusion for the treatment of hospitalized patients with complicated intra-abdominal infection. 45th Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington D.C., December 17, 2005.

44a. Kiffer C, Mendes C, Eagye KJ, Kuti JL, Nicolau DP. Pharmacodynamic

comparison of three carbapenems against extended-spectrum beta-lactamase producing Escherichia coli and Klebsiella spp. from the MYSTIC Program in Brazil (Abstract P1550). 16th European Congress of Clinical Microbiology and Infectious Diseases, Nice, France, April 1-4, 2006.

45a. Eagye KJ, Shore E, Dobkin E, Palter M, Nicolau DP, Kuti JL. Differing

epidemiology and resistance patterns of respiratory isolates from three intensive care units within the same institution (Abstract K-0259). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27, 2006.


11/7/11 23

46a. Eagye KJ, Nicolau DP, Kuti JL. Impact of superinfection on hospital length of stay and costs in patients with ventilator-associated pneumonia (Abstract K-0286). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 27, 2006.

47a. DeRyke CA, Kuti JL, Nicolau DP. Re-evaluation of current susceptibility

breakpoints for gram-negative rods based on pharmacodynamic assessment (Abstract D-0703). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 28, 2006.

48a. DeRyke CA, Sutherland C, Zhang B, Nicolau DP, Kuti JL. Pharmacokinetics

and serum bactericidal activity of high-dose daptomycin with and without co-administration of gentamicin against isolates of Staphylococcus aureus and Enterococcus species (Abstract A-0629). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 28, 2006.

49a. DeRyke CA, Kuti JL, Nicolau DP. Pharmacodynamic target attainment as a

surrogate marker for antibiotic efficacy in cost-effectiveness analyses (Abstract O-1465). 46th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 29, 2006.

50a. Kuti JL, Dowzicky M, Nicolau DP. A pharmacodynamic model to assess

tigecycline predicted efficacy compared with other antibiotics for hospital-acquired pneumonia (Abstract #213). 44th Annual Meeting of the Infectious Diseases Society of America, Toronto, Canada, October 12 – October 15, 2006.

51a. Kuti JL, Dowzicky M, Nicolau DP. Pharmacodynamic performance of

tigecycline compared with other antibiotics for complicated skin and soft tissue infections (Abstract P1-020). 10th Western Pacific Congress on Chemotherapy and Infectious Diseases, Fukuoka, Japan, December 4, 2006.

52a. Kiffer C, Kuti J, Mendes C, Sinto S, Koga P, Nicolau D. Pharmacodynamic

comparison of linezolid, teicoplanin, and vancomycin against clinical isolates of Staphylococcus aureus and coagulase negative staphylococci collected from hospitals in Brazil (Abstract). 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 to April 3, 2007.

53a. Kim A, Sutherland C, Kuti J, Nicolau D. Optimal piperacillin/tazobactam

dosing against Pseudomonas aeruginosa: prolonged or continuous infusion?


11/7/11 24

(Abstract). 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 to April 3, 2007.

54a. Eagye KJ, Kuti JL, Dowzicky M, Nicolau DP. Empiric therapy of secondary

peritonitis: a pharmacodynamic analysis of commonly prescribed antimicrobials, including tigecycline (Abstract). 17th European Congress of Clinical Microbiology and Infectious Diseases, Munich, Germany, March 31 to April 3, 2007.

55a. Eagye KJ, Kim A, Laohavaleeson S, Kuti JL, Nicolau DP. Impact of inadequate

antibiotic therapy on hospital length of stay in patients with complicated skin and skin structure infections (Abstract K-1256). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 18, 2007.

56a. Laohavaleeson S, Lolans K, Quinn J, Kuti JL, Nicolau DP. Identification of the

MexXY-OprM efflux system in cefepime resistant-ceftazidime susceptible Pseudomonas aeruginosa among clinical isolates from a US hospital (Abstract C2-1501). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 19, 2007.

57a. Laohavaleeson S, Barriere SL, Nicolau DP, Kuti JL. Cost-effectiveness of

telavancin versus vancomycin for the treatment of complicated skin and skin structure infections (Abstract O-1871). 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, September 19, 2007.

58a. St. Germain RM, Kuti JL, Doern GV, Girotto JE, Nicolau DP.

Pharmacodynamic target attainment of oral beta-lactams for the empiric treatment of acute otitis media in children (Abstract S07). Pediatric Pharmacy Advocacy Group Annual Meeting, Portsmouth VA, September 2007.

59a. Kuti JL, Nicasio AM, Shore E, Palter M, Pepe J, Nicolau DP. Outcomes of an

empiric antibiotic algorithm (EAA) for ventilator associated pneumonia (VAP) that considers local MIC distributions and pharmacodynamics (Abstract #1093). 45th Annual Meeting of the Infectious Diseases Society of America, San Diego, CA, October 4-7, 2007.

60a. Kim A, Nicolau DP, Kuti JL. Hospital costs and outcomes of patients

discharged with a diagnosis of pulmonary aspergillosis in the United States (Abstract # 189). 2007 Annual Meeting of the American College of Clinical Pharmacy, Denver, CO, October 16, 2007.


11/7/11 25

61a. Kim A, Sakoulas G, Kuti JL, Nicolau DP. Pharmacodynamic analysis of vancomycin versus linezolid against methicillin-resistant Staphylococcus aureus strains in New York (Abstract - RP18). 42nd Midyear Meeting of the American Society of Health System Pharmacists, Las Vegas, Nevada, December 2007.

62a. Crandon J, Kuti J, Jones R, Nicolau D. Pharmacodynamic target attainment

rates for 9 antibiotics against Escherichia coli, Klebsiella spp., and Pseudomonas aeruginosa isolates in USA hospitals (Abstract 44). 2008 Spring Research and Practice Forum of the American College of Clinical Pharmacy, Phoenix, AZ, April 8, 2008.

63a. Nicasio AM, Tessier PR, Shore E, Russomanno J, Knauft RF, Nicolau DP, Kuti

JL. Bronchopulmonary pharmacokinetics of micafungin in healthy adult volunteers (Abstract A-010). 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington D.C., October 25-28, 2008.

64a. Nicasio AM, Ariano RE, Zelenitsky SA, Crandon JL, Kim A, Kuti JL, Nicolau

DP. Population pharmacokinetics of high dose prolonged infusion cefepime in critically ill patients with ventilator-associated pneumonia (Abstract A-1880). 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington D.C., October 25-28, 2008.

65a. Kim A, Suecof LA, Sutherland CA, Gao L, Kuti JL, Nicolau DP. Tissue

penetration of daptomycin in diabetic versus healthy volunteers by in vivo microdialysis (Abstract A-1884). 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington D.C., October 25-28, 2008.

66a. Eagye KJ, Sutherland CA, Christensen H, Kuti JL, Nicolau DP. Prevalence of

Pseudomonas aeruginosa with reduced susceptibility to piperacillin/tazobactam at 39 hospitals (Abstract C2-201). 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington D.C., October 25-28, 2008.

67a. Nicasio AM, Eagye KJ, Nicolau DP, Shore E, Palter M, Pepe J, Kuti JL. A

pharmacodynamic based clinical pathway for empiric antibiotic choice in patients with ventilator associated pneumonia (Abstract K-490). 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington D.C., October 25-28, 2008.

68a. Eagye KJ, Kuti JL, Nicolau DP. Prior carbapenem use not associated with

infection with meropenem high-level resistant Pseudomonas aeruginosa (Abstract K-3492). 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington D.C., October 25-28, 2008.


11/7/11 26

69a. Kontou P, Kuti JL, Nicolau DP. Validation of the 2007 Infectious Diseases

Society of America/American Thoracic Society criteria in predicting severe community acquired pneumonia caused by Streptococcus pneumoniae (Abstract L-677). 48th Annual ICAAC / IDSA 46th Annual Meeting, Washington D.C., October 25-28, 2008.

70a. Khara A, Liu E, Kuti JL, Choudry S. Vancomycin accumulation in a patient

with osteomyelitis and normal renal function (student abstract). American Society of Health-System Pharmacists 2008 Midyear Clinical Meeting, Orlando, FL, December 8, 2008.

71a. Nicasio AM, Eagye JK, Kuti EL, Nicolau DP, Kuti JL. Hospital costs associated

with a pharmacodynamic based clinical pathway for empiric antibiotic choice in patients with ventilator associated pneumonia (Abstract 227). 2009 Spring Research and Practice Forum of the American College of Clinical Pharmacy, Orlando, FL, April 24-28, 2009.

72a. Bulik CC, Christensen H, Li P, Nicolau DP, Kuti JL. An in vitro

pharmacodynamic model of a human simulated high dose, prolonged infusion meropenem regimen against Klebsiella spp. producing the KPC carbapenemase (Abstract 231). 2009 Spring Research and Practice Forum of the American College of Clinical Pharmacy, Orlando, FL, April 24-28, 2009.

73a. Courter J, Kuti JL, Girotto JE, Nicolau DP. Optimizing bactericidal exposure

for β-lactams using prolonged and continuous infusions in the pediatric population (Abstract 332). 2009 Spring Research and Practice Forum of the American College of Clinical Pharmacy, Orlando, FL, April 24-28, 2009.

74a. Crandon JL, Bulik C, Kuti JL, Nicolau DP. Clinical pharmacodynamics of

cefepime in patients infected with Pseudomonas aeruginosa (Abstract A1-011). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.

75a. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL.

Pharmacodynamics (PD) of human simulated, high dose, prolonged infusion meropenem (MEM) against Pseudomonas aeruginosa (PSA) and carbapenemase producing Klebsiella pneumoniae (KPC) (Abstract A1-019). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.


11/7/11 27

76a. Bulik CC, Fauntleroy KA, Jenkins SG, Nicolau DP, Kuti JL. Comparison of meropenem (MEM) MICs for carbapenemase producing Klebsiella pneumoniae (KPC) by E-Test, Broth Microdilution (BMD), and VITEK 2 Methods (Abstract D-721). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.

77a. Crandon JL, Kuti JL, Nicolau DP. Comparison of simulated human exposures

of telavancin and vancomycin against methicillin resistant Staphylococcus aureus with ranging vancomycin MICs in a murine pneumonia model (Abstract A1-1292). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.

78a. Crandon JL, Banevicius MA, Fang AF, Crownover PH, Knauft RF, Pope JS,

Russomanno JH, Shore E, Nicolau DP, Kuti JL. Bronchopulmonary disposition of intravenous voriconazole and anidulafungin given in combination to healthy adults (Abstract). 49th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, September 12-15, 2009.

79a. Crandon JL, Ariano RE, Zelenitsky SA, Nicasio AM, Kuti JL, Nicolau DP.

Population pharmacokinetics to determine optimized meropenem dosing regimens in intensive care unit patients over three creatinine clearance ranges (Abstract 832). Society of Critical Care Medicine’s 39th Critical Care Congress, Miami, FL, January 9-13, 2010.

80a. Koomanachai P, Bulik CC, Kuti JL, Nicolau DP. Pharmacodynamic profiling or

intravenous antibiotics against gram-negative bacteria collected during the Tracking Resistance in the United States Today (TRUST) surveillance program (Abstract 1372). 14th International Congress on Infectious Diseases, Miami, FL, March 9-12, 2010.

81a. Keel RA, Kloft C, Schaeftlein A, Pope JS, Knauft RF, Muhlebach M, Nicolau

DP, Kuti JL. Population Pharmacokinetics of Intravenous and Oral Linezolid in Adults with Cystic Fibrosis. (Abstract No. A1-009). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.

82a. Keel RA, Sutherland CA, Aslanzadeh J, Nicolau DP, Kuti JL. Correlation

Between Vancomycin and Daptomycin MIC Values for Methicillin-Susceptible and -Resistant Staphylococcus aureus (MRSA) by Three Testing Methodologies. (Abstract No. D-162). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.


11/7/11 28

83a. Bulik CC, Wiskirchen DE, Shepard S, Sutherland CA, Kuti JL, Nicolau DP.

Tissue Penetration and Exposure Profile of Tigecycline in Diabetic Patients with Wound Infections by In Vivo Microdialysis. (Abstract No. D1-026). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.

84a. Wiskirchen DE, Koomanachi P, Nicasio AM, Nicolau DP, Kuti JL. In vitro

pharmacodynamics of pulmonary exposures of tigecycline alone and in combination with meropenem or rifampin against Klebsiella producing the KPC-2 carbapenemase. (Abstract No. A1-1147). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.

85a. Mazzei T, Breilh D, Kwa A, Montakantikul P, Roberts JA, Gomersall C, Mutters

R, Kuti JL, Nicolau DP. Carbapenem Pharmacodynamics Against Contemporary Non-fermenting Gram-negative Bacteria Isolated from European and Asia-Pacific Hospitals. (Abstract No. A1-1387). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.

86a. Furtado GH, Wiskirchen DE, Kuti JL, Nicolau DP. Validation of the PIRO

Score for Predicting Intensive Care Unit Mortality in Patients with Ventilator Associated P. (Abstract No. K-2187). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.

87a. Wiskirchen DE, Kuti JL, Nicolau DP. Validation the IBMP-10 Score for

Predicting Mortality in Patients with Ventilator Associated P. (Abstract No. K-2189). 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, September 12-15, 2010.

88a. Mazzei T, Breilh D, Mutters R, Kuti JL, Nicolau DP. Carbapenem

Pharmacodynamics (PD) against Pseudomonas and Acinetobacter Isolated from Intensive Care Units in European Hospitals: Results from the 2009 PASSPORT Program. (Abstract No. 1118). 23rd Annual Congress of the European Society of Intensive Care Medicine (ESICM), Barcelona, Spain, October 9-13, 2010.

89a. Bulik CC, Wiskirchen DE, Sutherland CA, Kuti JL, Nicolau DP. Concentration

Dependent Protein Binding of Tigecycline in Adult Diabetic Patients (Abstract No. 199). American College of Clinical Pharmacy, 2010 Annual Meeting, Austin, TX, October, 2010.


11/7/11 29

90a. Keel RA, Kuti JL, Sahm DF, Nicolau DP. Pharmacodynamic Target Attainment Rates for 6 Antibiotics against Pseudomonas aeruginosa Isolates in USA Hospitals (Abstract No. 2514). 48th Annual Meeting of the Infectious Diseases Society of America (IDSA), Vancouver, British Colombia, Canada, October 2010.

91a. Schaftlein A, Keel R, Kuti J, Kloft C. Linezolid concentrations in cystic fibrosis

patients: evaluation of competing pharmacokinetic models (Abstract No. K188:48). DPhG Jahrestagung 2010, Braunschweig, October 4-7, 2010.

92a. Housman ST, Tessier PR, Nicolau DP, Kuti JL. Physical compatibility of

telavancin with select intravenous drugs during simulated Y-site administration (Abstract No. 3-206). American Society of Health-System Pharmacist Midyear Clinical Meeting, Anaheim, CA, December 5-9, 2010.

93a. Wilde AM, Nailor MD, Nicolau DP, Kuti JL. Validation of a ventilator

associated pneumonia (VAP) clinical pathway using quantitative bronchoalveolar lavage for diagnosis (Abstract). 29th Annual Connecticut Infectious Disease Society (CIDS) Conference. Yale West Campus, CT, May 19, 2011.

dr. joe kuti’s scholarship - hartford hospital library/unassigned/kutischolarship.pdf · dr. joe...

Documents